Metsera (MTSR) Stock Price, News & Analysis

Company Overview

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Key Stats

• Today's Range: $12.83 to $14.22
• 50-Day Range: $13.08 to $32.08
• 52-Week Range: $12.30 to $32.81
• Volume: 839,821 shs
• Average Volume: 771,562 shs
• Market Capitalization: $1.47 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.00
• Consensus Rating: Buy

MTSR Stock Analysis - Frequently Asked Questions

How have MTSR shares performed this year?

Metsera's stock was trading at $29.50 at the beginning of the year. Since then, MTSR stock has decreased by 52.5% and is now trading at $14.00.
View the best growth stocks for 2025 here.

How were Metsera's earnings last quarter?

Metsera, Inc. (NASDAQ:MTSR) issued its earnings results on Wednesday, March, 26th. The company reported ($3.52) earnings per share for the quarter.

When did Metsera IPO?

Metsera (MTSR) raised $275 million in an initial public offering on Friday, January 31st 2025. The company issued 15,277,778 shares at a price of $18.00 per share.

When did Metsera's quiet period expire?

Metsera's quiet period expired on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. During Metsera's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Metsera?

Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/26/2025
• Today: 4/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MTSR
• Previous Symbol: NASDAQ:MTSR
• CIK: 2040807
• Web: N/A
• Phone: (212) 784-6595
• Fax: N/A
• Employees: 81
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $47.00
• High Stock Price Target: $56.00
• Low Stock Price Target: $38.00
• Potential Upside/Downside: +235.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 105,050,000
• Free Float: N/A
• Market Cap: $1.47 billion
• Optionable: N/A
• Beta: N/A